Deallus Consulting Ltd.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Deallus Consulting Ltd. - overview
Established
2004
Location
London, -, UK
Primary Industry
Business Support Services
About
Based in the UK, Deallus Consulting Ltd operates as a strategic intelligence consultancy specializing in the life sciences sector, providing insights and solutions to pharmaceutical and biotechnology companies. Founded in 2004 and headquartered in London, UK, Deallus Consulting Ltd specializes in strategic consultancy for the life sciences industry. The company has executed a total of 2 deals, with the most recent deal occurring on December 31, 2024. Peter Hempshall serves as the CEO, leading the firm through its various strategic initiatives.
Deallus Strategic Intelligence Consultancy offers a comprehensive suite of services tailored for the life sciences sector, focusing on competitive intelligence and strategic consulting. Their primary product offerings include therapeutic area strategy development, market access solutions, brand strategy development, and forecasting services. These services assist pharmaceutical, biotechnology, and med-tech companies in navigating complex market dynamics and regulatory environments. Deallus engages in peer-to-peer partnerships with clients, acting as an extension of their internal teams to develop bespoke solutions that meet specific organizational needs.
The firm operates in key global markets, including North America, Europe, and Asia, serving a diverse client base that encompasses leading global pharmaceutical companies, emerging biopharma startups, and other stakeholders in the healthcare industry. In 2021, Deallus reported a revenue of USD 8. 08 mn, with an EBITDA of USD 656,183. The company generates revenue primarily through business-to-business transactions, capitalizing on its consultancy services for pharmaceutical and biotechnology firms, structured as project-based contracts that allow tailored insights critical for clients' decision-making processes.
In December 2024, Deallus Consulting Ltd was acquired by GlobalData Plc from ARCHIMED, although the financial terms of the acquisition were not disclosed. The rationale behind this acquisition is to enhance GlobalData Plc's insights and decision support services. Moving forward, Deallus may focus on expanding its service offerings and geographic outreach, although specific products and market entry plans have not yet been detailed.
Current Investors
ARCHIMED
Primary Industry
Business Support Services
Sub Industries
Consulting Services, e-Financial
Website
www.deallus.com
Company Stage
Mature - Buyout
Total Amount Raised
Subscriber access only
Deallus Consulting Ltd. - timeline of key events
Deallus Consulting Ltd. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Trade Sale | Completed | Deallus Consulting Ltd. | - | ||||||||
| Buyout | Completed | Deallus Consulting Ltd. | - |
Displaying 1 - 2 of 2
Deallus Consulting Ltd. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.